BioNTech SE - ADR vs iShares Self-Driving EV and Tech — how do they compare? BioNTech SE - ADR trades at $90.88 (market cap $22.86B), while iShares Self-Driving EV and Tech trades at $36.65. The key difference: iShares Self-Driving EV and Tech is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | IDRV | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Sector/Thematic |
52-Week High | $119.34 | $45.48 |
52-Week Low | $83.89 | $32.13 |
Enterprise Value | $6.53B | — |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
IDRV trades at $36.35, down 1.38% with a bearish technical signal from moving averages. The ETF shows neutral oscillators but lacks disclosed fundamental ratios. Recent news highlights strong global EV sales growth, particularly in China and Europe, driven by high fuel prices and policy support, though U.S. adoption lags.
Outlook is mixed: positive EV industry momentum contrasts with technical weakness and U.S. market challenges. Key risks include regulatory shifts, competition, and reliance on macroeconomic factors. Investors should weigh sector growth against ETF-specific performance and market sentiment.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →